Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 following Single Ascending Dose Administration to Healthy Subjects who are Overweight or Obese

Trial Identifier: D8750C00001
Sponsor: AstraZeneca
Start Date: September 2022
Primary Completion Date: December 2023
Study Completion Date: December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Japanese Translation

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206
US, MD Brooklyn, MD, US, 21225